Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 The ... will be a supporting organization of the Johnson ... sterilization in 2016. Johnson & Johnson ... of high-profile superbug infections in endoscopes. J&J ran ... issues between 1976 and 2003 on advances in ...
(Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
(Date:5/28/2015)... -- National Community Pharmacists Association (NCPA) CEO B. ... in response to a new report released ... number of generic drug costs increased substantially in 2013: ... expressed by NCPA and underscores the need for action ... Moreover, a 2015 survey of 700 community pharmacists concluded ...
Breaking Medicine Technology:PDA Announces Support for the Johnson & Johnson Kilmer Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2
... (Nasdaq: CPIX ) announced today that it ... closes on Thursday, November 11, 2010.  A conference call and ... 2010 at 5:00 p.m. Eastern Time to discuss the results. ... (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast ...
... N.J., Oct. 28 Ten pharmacy professionals were saluted on ... event was created to honor the future of pharmacy and ... practice. Pharmacy Times and Parata partnered to recognize ... the way for the industry,s future. Mark ...
Cached Medicine Technology:Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010 2Next-Generation Pharmacist Winner Announced 2Next-Generation Pharmacist Winner Announced 3
(Date:5/28/2015)... (PRWEB) May 28, 2015 Dr. Paul ... surgeons , has announced that the new Houston Surgery ... American Association of Accreditation of Ambulatory Surgery Facilities awarded ... center . , According to Dr. Vitenas, the ... the standards of a Class C ambulatory surgery facility. ...
(Date:5/28/2015)... The connected car is gaining more traction ... vehicles have some iteration of a connected offering in ... insurance companies as the data collected can be used ... insurance (UBI). This is the primary reason that 800+ ... 2015 Conference & Exhibition. , Andrew Pym, TU ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Hexagon Geospatial ... (BHI) , a provider of engineering, spatial data and ... and analyze thousands of point clouds for urban change ... 2012 to 2014, the BHI Spatial Data Division implemented ... digital stereo aerial imagery. Collected by a variety of ...
(Date:5/28/2015)... 2015 lifeIMAGE announced today ... financing led by Cambia Health Solutions (Portland, ... transforming health care by creating a person-focused and economically ... network for exchanging medical imaging, will use this financing ... the breadth of its network capabilities and implement the ...
(Date:5/28/2015)... Westport, CT (PRWEB) May 28, 2015 ... mobile monitoring software, announced their partnership with ... their kids’ online activity. The partnership ... programs with WebWatcher’s comprehensive parental monitoring software ... Detective Rich Wistocki, BeSure Consulting's passion is ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 3Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:WebWatcher Partners with BeSure Consulting 2Health News:WebWatcher Partners with BeSure Consulting 3
... Roche and Memory Pharmaceuticals (Nasdaq: MEMY ... a definitive merger agreement for Roche to acquire all ... transaction for an aggregate price of approximately USD 50 ... Memory Pharmaceuticals develops innovative drug candidates for the treatment ...
... 25 Pennsylvania will benefit a potential $16 million ... Botvin LifeSkills Training program, a drug abuse ... released by the Prevention Research Center at Pennsylvania ... of this highly effective program yields a return on ...
... DETROIT, Nov. 24 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext ... response to the FDA warning letter that was received ... requested a response from Caraco,within 15 business days, ending ... As previously disclosed, the warning letter was issued ...
... , , MONDAY, Nov. 24 (HealthDay News) -- A drug ... and caused fewer side effects than the widely-used migraine ... drug maker Merck & Co. , Zolmitriptan and other ... side effects, including dizziness, tingling and numbness of the ...
... University of California, San Diego (UCSD) and the Moores ... novel drug target for an often difficult-to-treat form of ... pattern of a specific family of enzymes in patients ... of adult leukemia. , Paul Insel, M.D., professor ...
... announced on Friday that Garvan endocrinologist and PhD student, Dr ... the AAAS Science "Dance your PhD" contest. See ... Science magazine challenged researchers around the world to interpret ... share it with the world on YouTube by mid-November. ...
Cached Medicine News:Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 2Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 4Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 2Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter 2Health News:New Migraine Drug Shows Promise 2Health News:UCSD researchers identify potential new drug target for chronic leukemia 2Health News:Ph.D. student Sue Lynn Lau dances her way to Chicago 2
... For Usage: ,Used primarily ... monitoring lumen is used for: ... gases especially end-tidal CO2. ... , Introducing medication. , ...
Indications For Usage: ,Jet ventilation....
Indications For Usage: , Airway management during surgical procedures. , Long-term ventilatory management. ...
Indications For Usage: , Oral Surgery. , Maxillofacial surgery. ...
Medicine Products: